com701

Colo-rectal Cancer

Compugen LtdPhase 1Dormant

CCC

50/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 37/ 100
Competitive Position: 89/ 100

Competitive context

840 Active assets in the Colo-rectal Cancer cohort.

Asset / Sponsor	Phase	Rating
Desflurane Peter MacCallum Cancer Centre, Australia	Phase 4	BBB
MARBLE DUST James Varani	Phase 2/3	BB
FLUOROURACILUM Washington University School of Medicine	Phase 4	BB
PANITUMUMAB M.D. Anderson Cancer Center	Phase 3	BB
Cetuximab Shanghai Henlius Biotech	Phase 4	BB

View all 50 →

Same molecule, other indications

com701 is also rated in:

ovarian cancerDormant

CCC

Indicative ·

55 / 100

endometrial cancerDormant

CCC

Indicative ·

48 / 100

colorectal carcinomaDormant

CC

Indicative ·

47 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.